Dr. Kalpana Gupta Shekhawat on Nattokinase: Human Study Shows 36% Plaque Regression
Dr. Kalpana Gupta Shekhawat, Chairperson, Functional & Metabolic Medicine Academy, shared a post on LinkedIn:
“Nattokinase in Cardiovascular Care: Insights from Human Studies
Reversing established atherosclerosis remains one of the most difficult challenges in cardiovascular medicine. Despite significant advances in lipid-lowering therapies, most conventional approaches primarily aim to slow disease progression rather than induce meaningful regression of existing plaque. In this evolving landscape, nattokinase has emerged as a growing area of interest within preventive and integrative cardiology.
Nattokinase is a potent fibrinolytic enzyme derived from natto, a traditional Japanese fermented soybean food consumed for centuries. While epidemiological observations from Japan have long suggested cardiovascular benefits, recent human clinical studies have begun to elucidate its therapeutic relevance in vascular disease.
Evidence for Plaque Regression
Among the most striking findings is a large human study reporting a 36% reduction in carotid artery plaque area in individuals supplemented with nattokinase—an outcome rarely achieved in routine clinical practice.
In this study, nattokinase was administered at a dose of 10,800 fibrinolytic units (FU) per day. Beyond merely slowing atherosclerotic progression, supplementation led to measurable regression of existing plaque and improvement in arterial structure, suggesting a disease-modifying effect rather than simple risk reduction.
Effects on Lipid Profile
In addition to its effects on plaque burden, nattokinase has demonstrated favorable modulation of lipid metabolism. Multiple clinical studies indicate that supplementation can:
Reduce LDL cholesterol
Increase HDL cholesterol
The simultaneous improvement in lipid balance alongside plaque regression is particularly noteworthy, as these outcomes are seldom achieved with a single intervention.
Comparison with Statin Therapy
Available evidence suggests that nattokinase may provide lipid-lowering effects comparable to statins, while potentially exerting a greater influence on plaque dynamics in select populations. While statins remain foundational in cardiovascular risk reduction, their capacity to reverse established plaque is limited.
Nattokinase appears to act through multiple complementary mechanisms, including enhanced fibrinolysis, improved blood rheology, reduced blood viscosity, improved microcirculatory flow, and support of endothelial function. Collectively, these effects may explain its influence on atherosclerotic plaque beyond cholesterol lowering alone.
Clinical Perspective
As cardiovascular care moves beyond cholesterol-centric models toward addressing vascular biology itself, therapies that influence plaque composition, fibrinolysis, and endothelial health are becoming increasingly relevant. Human clinical data suggest that nattokinase may offer benefits extending beyond conventional lipid lowering, positioning it as a promising adjunct within comprehensive cardiovascular prevention strategies.”
Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
May 28, 2026, 16:19James Farrell: The Power of Linked Electronic Health Records for Understanding Real Patient Journeys
-
May 28, 2026, 16:19Michael Makris: I Hope The Bleeding Disorders Community Supports Kedrion Initiative for FV Deficiency
-
May 28, 2026, 16:16Kamalben Prajapati at Vascular Discovery Conference 2026
-
May 28, 2026, 16:11Laura Dormer: Real-World Safety of DOACs vs LMWH in Cancer-Associated VTE Acroos Europe
-
May 28, 2026, 16:08Esau Martinez Ruiz: Proud to be Part of the Faculty at BDFLOW Summit26 in Brussels
-
May 28, 2026, 16:06Francisco Chacon-Lozsan: Why Anticoagulation in the ICU is not One Protocol?
-
May 28, 2026, 16:04When was the Last Time You Had Your Cholesterol Checked? – UNC Health
-
May 28, 2026, 16:03Paul Bolaji: ACTIVATE Study in Ghana Demonstrates Over 400% Increase in Stroke Thrombolysis
-
May 28, 2026, 15:57Lysanne van der Wal – Smit: Improving Care for Women Affected by HG at ICHG 2026